Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Franklin Resources Inc.

Franklin Resources Inc. lessened its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 13.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 75,702 shares of the company’s stock after selling 12,241 shares during the period. Franklin Resources Inc.’s holdings in Neumora Therapeutics were worth $1,000,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Amalgamated Bank grew its holdings in shares of Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares during the last quarter. Quarry LP acquired a new position in Neumora Therapeutics during the 2nd quarter valued at approximately $98,000. SkyOak Wealth LLC bought a new position in Neumora Therapeutics during the 2nd quarter worth $147,000. Principal Financial Group Inc. acquired a new stake in Neumora Therapeutics in the second quarter worth $166,000. Finally, Intech Investment Management LLC acquired a new stake in Neumora Therapeutics in the third quarter worth $175,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $11.33 on Friday. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00. The stock has a market capitalization of $1.83 billion, a PE ratio of -6.06 and a beta of 3.34. The firm has a 50 day simple moving average of $11.07 and a 200-day simple moving average of $11.58.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the previous year, the company earned ($1.14) earnings per share. On average, analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on NMRA. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research report on Monday, December 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $23.40.

Insider Buying and Selling

In other news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares of the company’s stock, valued at $342,303. The trade was a 41.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares in the company, valued at $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.40% of the stock is owned by corporate insiders.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.